Chemotherapy Drug Development Immunity 
European Pharmaceutical Review
DECEMBER 28, 2023
Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.
pharmaphorum
JUNE 8, 2021
All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% of the global market in the same year”. million in 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 5, 2021
Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.
Pharmaceutical Technology
AUGUST 12, 2022
Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab.
Pharmaceutical Technology
FEBRUARY 24, 2023
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
pharmaphorum
JANUARY 26, 2022
It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.
Pharmaceutical Technology
FEBRUARY 13, 2023
Surprisingly, ARV-471 has progressed to Phase III to be evaluated in a less heavily pretreated population where all patients have received CDK4/6 inhibitors, but unlike the Phase II, patients who have received Faslodex or chemotherapy for advanced disease will be excluded. with Calquence, 16% with Imbruvica, NCT02477696).
Expert insights. Personalized for you.
84 
Let's personalize your content